Search

Displaying results 2681 - 2690 of 7018 in total
  1. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for

  2. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells. … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.

    Synonyms: (618-THREONINE,709-ASPARTIC ACID)VON WILLEBRAND FACTOR HOMO SAPIENS (1381A>T,1472H>D VARIANT) BLOOD COAGULATION FACTOR
  3. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  4. Drug

    Amsacrine

    go.drugbank.com/drugs/DB00276
    ApprovedInvestigationalWithdrawn

    Aminoacridine derivative that is a potent intercalating antineoplastic agent. … It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Etofamide

    go.drugbank.com/drugs/DB13258
    Approved

    Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].

  6. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  7. Drug

    Chamaecyparis obtusa leaf

    go.drugbank.com/drugs/DB14686
    Investigational

    Mixtures: Rhodd Ato Repair Body So Ap
  8. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. … It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)

  9. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.

  10. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    Garetosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP). … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic